Immunogenicity and Safety of an Inactivated COVID-19 Vaccine
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT04953325 |
Recruitment Status :
Completed
First Posted : July 7, 2021
Last Update Posted : April 14, 2022
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
COVID-19 | Biological: Inactivated COVID-19 Vaccine Biological: 23-valent pneumococcal polysaccharide vaccine Biological: Inactivated Hepatitis A Vaccine | Phase 4 |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 270 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Prevention |
Official Title: | Immunogenicity and Safety of an Inactivated COVID-19 Vaccine for Prevention of COVID-19 in Healthy Population Aged 18 Years and Older |
Actual Study Start Date : | July 9, 2021 |
Actual Primary Completion Date : | October 31, 2021 |
Actual Study Completion Date : | January 31, 2022 |

Arm | Intervention/treatment |
---|---|
Experimental: Experimental Group
180 subjects (including 90 adults aged 18-59 years and 90 elderly aged 60 year and older)will receive two doses of inactivated COVID-19 vaccine on day 0 and day 28
|
Biological: Inactivated COVID-19 Vaccine
600SU inactivated virus in 0·5 mL of aluminium hydroxide solution per injection
Other Name: CoronaVac |
Placebo Comparator: Control Group
90 subjects (including 45 adults aged 18-59 years and 45 elderly aged 60 year and older)will receive one dose of 23-valent pneumococcal polysaccharide vaccine on day 0 and one dose of Inactivated Hepatitis A Vaccine on day 28
|
Biological: 23-valent pneumococcal polysaccharide vaccine
25μg each of the following serotypes/each dose (0.5ml): 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F, and 33F Biological: Inactivated Hepatitis A Vaccine 500SU inactivated Hepatitis A virus in 1 mL of aluminium hydroxide solution per injection. |
- Seroconversion rate of the neutralizing antibody to SARS-CoV-2 [ Time Frame: Day 28 after the second dose ]Seroconversion rate of the neutralizing antibody to SARS-CoV-2 at day 28 after the second dose of inactivated COVID-19 vaccine
- Seroconversion rate of the neutralizing antibody to SARS-CoV-2 [ Time Frame: Day 4, 14, 32,42 and 56 after the first dose ]Seroconversion rate of the neutralizing antibody to SARS-CoV-2 at different points after vaccination
- Seropositivity rate of the neutralizing antibody to SARS-CoV-2 [ Time Frame: Day 4, 14, 28, 32,42 and 56 after the first dose ]Seropositivity rate of of the neutralizing antibody to SARS-CoV-2 at different points after vaccination
- GMT of the neutralizing antibody to SARS-CoV-2 [ Time Frame: Day 4, 14, 28, 32,42 and 56 after the first dose ]GMT of of the neutralizing antibody to SARS-CoV-2 at different points after vaccination
- GMI of the neutralizing antibody to SARS-CoV-2 [ Time Frame: Day 4, 14, 28, 32,42 and 56 after the first dose ]GMT of of the neutralizing antibody to SARS-CoV-2 at different points after vaccination
- Geometric mean concentrations of anti-pneumococcal antibody for 23 serotypes (ELISA) [ Time Frame: Day 28 after vaccination of 23-valent pneumococcal polysaccharide vaccine ]Geometric mean concentrations of anti-pneumococcal antibody for 23 serotypes (ELISA) at day 28 after vaccination of 23-valent pneumococcal polysaccharide vaccine
- Seroconversion rate of anti-pneumococcal antibody for 23 serotypes (ELISA) [ Time Frame: Day 28 after vaccination of 23-valent pneumococcal polysaccharide vaccine ]Seroconversion rate of anti-pneumococcal antibody for 23 serotypes (ELISA) at day 28 after vaccination of 23-valent pneumococcal polysaccharide vaccine
- Seroconversion rate of the hepatitis A antibody by Electrochemiluminescence [ Time Frame: Day 28 after vaccination of Inactivated Hepatitis A Vaccine ]Seroconversion rate of the hepatitis A antibody at day 28 after vaccination of Inactivated Hepatitis A Vaccine
- Seropositivity rate of the hepatitis A antibody by Electrochemiluminescence [ Time Frame: Day 28 after vaccination of Inactivated Hepatitis A Vaccine ]Seropositivity rate of the hepatitis A antibody at day 28 after vaccination of Inactivated Hepatitis A Vaccine
- GMT of the hepatitis A antibody by Electrochemiluminescence [ Time Frame: Day 28 after vaccination of Inactivated Hepatitis A Vaccine ]GMT of the hepatitis A antibody at day 28 after vaccination of Inactivated Hepatitis A Vaccine
- GMI of the hepatitis A antibody by Electrochemiluminescence [ Time Frame: Day 28 after vaccination of Inactivated Hepatitis A Vaccine ]GMI of the hepatitis A antibody at day 28 after vaccination of Inactivated Hepatitis A Vaccine
- Occurrence of abnormal changes of laboratory safety examinations [ Time Frame: Day 4, 14, 28, 32,42 and 56 after the first dose ]Occurrence of abnormal changes of laboratory safety examinations (Platelet factor 4 HIT, blood sugar, ESR, White blood cell count, hemoglobin, platelet count and Coagulation function index)

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
- Healthy population aged 18 years and above;
- The subjects can understand and voluntarily sign the informed consent form;
- Proven legal identity.
Exclusion Criteria:
- History of SARS-CoV-2 infection;
- Have received any COVID-19 vaccine;
- Participants with abnormal fasting blood glucose or diabetes;
- History of asthma, history of allergy to the vaccine or vaccine components,or serious adverse reactions to the vaccine, such as urticaria, dyspnea,and angioedema;
- Autoimmune disease or immunodeficiency / immunosuppression;
- Severe chronic diseases, severe cardiovascular diseases, hypertension and diabetes that cannot be controlled by drugs, liver or kidney diseases, malignant tumors, etc.;
- Severe neurological disease (epilepsy, convulsions or convulsions) or mental illness;
- Thyroid disease or history of thyroidectomy, spleenlessness, functional spleenlessness, spleenlessness or splenectomy resulting from any condition;
- Diagnosed abnormal blood coagulation function (eg, lack of blood coagulation factors, blood coagulopathy, abnormal platelets) or obvious bruising or blood coagulation;
- Diseases or factors that are prone to thrombosis or bleeding, such as thrombophlebitis, major surgery/trauma, hereditary thrombotic disorder, sepsis, inflammatory bowel disease, severe varicose veins, May-Thurner syndrome, fibrinolytic activity enhancement disease, history of cardiac stent surgery, allergic purpura, etc.;
- Immunosuppressive therapy, cytotoxic therapy, inhaled corticosteroids (excluding allergic rhinitis corticosteroid spray therapy, acute noncomplicated dermatitis superficial corticosteroid therapy) in the past 6 months;
- Abnormal hematological laboratory test results outside the reference range during previous physical examination within one year: Blood routine indicators (white blood cell count, hemoglobin, platelet count), Coagulation function test (prothrombin time PT, activated partial prothrombin time APTT, fibrinogen FIB, thrombin time TT, international standardized ratio INR, D-dimer), other indicators (blood glucose, platelet factor 4 HIT ELISA, erythrocyte sedimentation rate);
- History of alcohol or drug abuse;
- Receipt of blood products within in the past 3 months;
- Receipt of other investigational drugs in the past 30 days;
- Receipt of attenuated live vaccines in the past 14 days;
- Receipt of inactivated or subunit vaccines in the past 7 days;
- Axillary temperature >37.0°C;
- Already pregnant (including a positive urine pregnancy test) or are breastfeeding, planning to get pregnant within 3 months;
- History of taking aspirin drugs and other drugs that affect blood coagulation;
- According to the investigator's judgment, the subject has any other factors that are not suitable for participating in the clinical trial.

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04953325
China, Shandong | |
Rushan City Center for Disease Control and Prevention | |
Weihai, Shandong, China, 250014 |
Principal Investigator: | Li Zhang, Master | Shandong Provincial Center for Disease Control and Prevention |
Responsible Party: | Sinovac Research and Development Co., Ltd. |
ClinicalTrials.gov Identifier: | NCT04953325 |
Other Study ID Numbers: |
PRO-nCOV-MA4004-SD |
First Posted: | July 7, 2021 Key Record Dates |
Last Update Posted: | April 14, 2022 |
Last Verified: | July 2021 |
Studies a U.S. FDA-regulated Drug Product: | No |
Studies a U.S. FDA-regulated Device Product: | No |
COVID-19 Respiratory Tract Infections Infections Pneumonia, Viral Pneumonia Virus Diseases Coronavirus Infections Coronaviridae Infections |
Nidovirales Infections RNA Virus Infections Lung Diseases Respiratory Tract Diseases Vaccines Heptavalent Pneumococcal Conjugate Vaccine Immunologic Factors Physiological Effects of Drugs |